Maze TherapeuticsMAZE +1.31%14 PB Ratio is 3.93 as of Jun. 25, 2026, which is 1% above its 10-year median of 3.88. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, Maze Therapeutics ranks worse than 62.04% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Maze Therapeutics PB Ratio Related Terms
Maze Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Maze Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Maze Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maze Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maze Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Maze Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Maze Therapeutics (MAZE) has a PB Ratio of 3.93 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Maze Therapeutics and its competitors. This is near median its historical median of 3.88. Over the past decade, Maze Therapeutics' PB Ratio has ranged from 1.17 to 8.40. According to the industry distribution chart, Maze Therapeutics ranks #765 out of 1233 companies in the Biotechnology industry, placing it in the top 62%.
Is Maze Therapeutics' PB Ratio too high?
Maze Therapeutics' current PB Ratio of 3.93 is near median its 10-year median of 3.88. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 8.40. The Biotechnology industry median PB Ratio is 2.80. Maze Therapeutics' value of 3.93 is 40.4% above this industry median. Based on the distribution chart, Maze Therapeutics ranks #765 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' PB Ratio compare to FTRE and ARDX?
According to the Biotechnology industry distribution chart, Maze Therapeutics ranks #765 out of 1233 companies for PB Ratio. This places Maze Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Maze Therapeutics' value of 3.93 is 40.4% above this benchmark. Historically, Maze Therapeutics' own PB Ratio has ranged from 1.17 to 8.40 over the past decade. While the company's 10-year median is 3.88 vs. the industry median of 2.80, Maze Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maze Therapeutics's current PB Ratio of 3.93 is 40.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Maze Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maze Therapeutics's current PB Ratio is 3.93, which is near median its own 10-year median of 3.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current PB Ratio of 3.93. The current PB Ratio is 3.93, which is near median its 10-year median of 3.88 and 40.4% above the Biotechnology industry median of 2.80. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current PB Ratio is 3.93 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score
Get the complete analysis for MAZE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAZE has been successfully added to your 
